1.I O Ellis,
S Humphreys,
M Michell,
S E Pinder,
C A Wells,
H D Zakhour: UK National Coordinating Commmittee for Breast Screening Pathology; European Commission Working Group on Breast Screening Pathology.. Best Practice No 179.
Guidelines for breast needle core biopsy handling and reporting in breast screening assessment.
J Clin Pathol.
2004;57(9):897-902.
2.
Rageth CJ,
O'Flynn EAM,
Pinker K,
Kubik-Huch RA,
Mundinger A,
Decker T,
Tausch C,
Dammann F,
Baltzer PA,
Fallenberg EM,
Foschini MP,
Dellas S,
Knauer M,
Malhaire C,
Sonnenschein M,
Boos A,
Morris E,
Varga Z.
Second International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions).
Breast Cancer Res Treat.
2018 Nov 30.
doi: 10.1007/s10549-018-05071-1.
[Epub ahead of print]
3.
Forester ND,
Lowes S,
Mitchell E,
Twiddy M.
High risk (B3) breast lesions: What is the incidence of malignancy for individual lesion subtypes? A systematic review and meta-analysis..
Eur J Surg Oncol.
2018 Dec 11.
pii: S0748-7983(18)32030-4.
doi: 10.1016/j.ejso.2018.12.008.
[Epub ahead of print]
4.
WHO.
Lakhani SREI,
Schnitt SJ,
Tan PH,
van de Vijver MJ (2012) WHO classification of tumours of the breast,
fourth edition 2012.
International Agency for Research on Cancer,
Lyon.
5.
NHSBSP.
NHS Breast Screening Programme Clinical guidance for breast cancer screening assessment NHSBSP publication number 49 Fourth edition November 2016.
6.Rageth CJ. O’Flynn EA , Comstock C,
Kurtz C,
Kubik R ,
Madjar H , Lepori,
D,
Kampmann G,
Mundinger A,
Baege A,
Decker T, Hosch S,
Tausch C ,
Delaloye JF, Morris E,
Varga Z..
First International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions).
Breast Cancer Res Treat 2016;159(2):203-13.
7.Perry N,
Broeders M,
de Wolf C,
Tornberg S,
Holland R,
von Karsa L,
eds.
European Guidelines for Quality Assurance in Breast Cancer Screening and Diagnosis,
4th ed.
Luxembourg,
Germany: Office for Official Publications of the European Communities,
European Commission; 2006:232–235.
8.
NHS Breast Screening Programme.
Clinical guidance for breast cancer screening assessment NHSBSP publication number 49 Fourth edition November 2016.
9.Lakhani SREI,
Schnitt SJ,
Tan PH,
van de Vijver MJ (2012).
WHO classification of tumours of the breast,
fourth edition 2012.
International Agency for Research on Cancer,
Lyon.
10.Cohen MA,
Newell MS.
Radial Scars of the Breast Encountered at Core Biopsy: Review of Histologic,
Imaging,
and Management Considerations.
AJR 2017; 209:1–10.
11.Houssami N,
Ciatto S,
Bilous M,
Vezzosi V,
Bianchi S.
Borderline breast core needle histology: predictive values for malignancy in lesions of uncertain malignant potential (B3).Br J Cancer.
2007 Apr 23;96(8):1253-7.
12.Preibsch H,
Wanner LK,
Staebler A,
Hahn M,
Siegmann-Luz KC.
Malignancy rates of B3 lesions in breast magnetic resonance imaging. do all lesions have to be excised? BMC Med Imaging.
2018 Sep 10;18(1):27-33.
13.Falomo E,
Adejumo C,
Carson KA,
Harvey S,
Mullen L,
Myers K.
Variability in the Management Recommendations Given for High risk Breast Lesions Detected on Image-guided Core Needle Biopsy at U.S.
Academic Institutions.Curr Probl Diagn Radiol.
2018 Jun 27.
pii: S0363-0188(18)30067-7.
doi: 10.1067/j.cpradiol.2018.06.004.
[Epub ahead of print].
14.Schnitt SJ,
Collins LC.
Biopsy interpretation of the breast.
3rd Edition.
Wolters Kluwer.
2018